Loading
A Seattle safety trial of helper T cells grown from patients' own blood to recognise melanoma. It ran from 2001 to 2008 and the registry posts no results.
The registry describes a phase I safety study of cellular adoptive immunotherapy using autologous CD4+ antigen-specific T-cell clones in metastatic melanoma, started in November 2001 and completed in August 2008, with an estimated enrolment of 18 (ClinicalTrials.gov NCT00045357). Cassian Yee is listed as study chair; the sponsor is Fred Hutchinson Cancer Center with the National Cancer Institute as collaborator (ClinicalTrials.gov NCT00045357). No results are posted.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/